Literature DB >> 16893437

Epidemiology, prescribing patterns and resource use associated with overactive bladder in UK primary care.

I A O Odeyemi1, H A Dakin, R A O'Donnell, J Warner, A Jacobs, P Dasgupta.   

Abstract

This study aimed to estimate the incidence and prevalence of overactive bladder (OAB) symptoms in the UK and analyse the use of anticholinergic/antispasmodic medications and other healthcare resources within UK general practice. Patients with a record of urinary frequency, urgency, nocturia, urge incontinence or irritable/unstable bladder between 1987 and 2004 were identified from the General Practice Research Database. Demographic characteristics, referrals, consultations, investigations and prescriptions for medications licensed for use in OAB were identified. Regression analyses were used to identify the factors determining switches between medications, referrals and use of healthcare resources. The overall prevalence of OAB-related symptoms was 3.87 per 1000 persons, with an incidence of 2.79 per 1000 person-years. Among 68,910 patients with OAB symptoms, 19,444 (28.2%) received anticholinergic medication, of whom 14,454 (74.3%) received one drug and 4055 (20.9%) received two medications sequentially. Overall, 59.1% of patients were referred to relevant secondary care specialities, 2.8% underwent urinary tests/investigations in primary care and 0.2% were seen by a continence nurse. Resource use was higher among patients who tried several different medications. In conclusion, this study suggests that OAB may be under-diagnosed in the UK and that current guidelines recommending use of anticholinergic medication, continence nurse consultations and urinary tests/investigations are inadequately followed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16893437     DOI: 10.1111/j.1742-1241.2006.01057.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  13 in total

1.  Incidence of and factors associated with anticholinergic drug use among Norwegian women with urinary incontinence.

Authors:  Siri A Mauseth; Svetlana Skurtveit; Arnulf Langhammer; Olav Spigset
Journal:  Int Urogynecol J       Date:  2017-11-04       Impact factor: 2.894

2.  Anticholinergic medication use for female overactive bladder in the ambulatory setting in the United States.

Authors:  Rujin Ju; Joanne Garrett; Jennifer M Wu
Journal:  Int Urogynecol J       Date:  2013-10-25       Impact factor: 2.894

3.  Association of overactive bladder and C-reactive protein levels. Results from the Boston Area Community Health (BACH) Survey.

Authors:  Varant Kupelian; Raymond C Rosen; Claus G Roehrborn; Pradeep Tyagi; Michael B Chancellor; John B McKinlay
Journal:  BJU Int       Date:  2011-12-16       Impact factor: 5.588

4.  Antimuscarinic persistence patterns in newly treated patients with overactive bladder: a retrospective comparative analysis.

Authors:  Antoni Sicras-Mainar; Javier Rejas; Ruth Navarro-Artieda; Alba Aguado-Jodar; Amador Ruiz-Torrejón; Jordi Ibáñez-Nolla; Marion Kvasz
Journal:  Int Urogynecol J       Date:  2013-11-06       Impact factor: 2.894

5.  Antimuscarinic Medication Use in Elderly Patients with Overactive Bladder.

Authors:  Nandita Kachru; Sneha Sura; Satabdi Chatterjee; Rajender R Aparasu
Journal:  Drugs Aging       Date:  2016-10       Impact factor: 3.923

6.  Association of diuretic use and overactive bladder syndrome in older adults: a propensity score analysis.

Authors:  O James Ekundayo; Alayne Markland; Christina Lefante; Xuemei Sui; Patricia S Goode; Richard M Allman; Mahmud Ali; Christy Wahle; Phillip L Thornton; Ali Ahmed
Journal:  Arch Gerontol Geriatr       Date:  2008-08-26       Impact factor: 3.250

Review 7.  Pharmacotherapy of urinary incontinence.

Authors:  Anastasios Athanasopoulos; Petros Perimenis
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-11-12

8.  Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study.

Authors:  Nandita Kachru; Holly M Holmes; Michael L Johnson; Hua Chen; Rajender R Aparasu
Journal:  Curr Med Res Opin       Date:  2021-05-13       Impact factor: 2.705

9.  Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom.

Authors:  Samuel Aballéa; Khaled Maman; Katia Thokagevistk; Jameel Nazir; Isaac A O Odeyemi; Zalmai Hakimi; Andy Garnham; Mondher Toumi
Journal:  Clin Drug Investig       Date:  2015-02       Impact factor: 2.859

10.  Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain.

Authors:  Antoni Sicras-Mainar; Javier Rejas; Ruth Navarro-Artieda; Alba Aguado-Jodar; Amador Ruiz-Torrejón; Jordi Ibáñez-Nolla; Marion Kvasz
Journal:  BMC Urol       Date:  2013-10-21       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.